Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies

Affiliations

• ¹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
• ² Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
• ³ Department of Imaging, Centre for Radiopharmaceutical Chemistry, University College London, London, UK.
• ⁴ Department of Chemistry, University College London, London, UK.
• ⁵ Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.
• ⁶ Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK.
• ⁷ Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
• ⁸ Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK.
• ⁹ UK Dementia Research Institute, Queen Square Institute of Neurology, University College London, London, UK.
• ¹⁰ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. michael.scholl@neuro.gu.se.
• ¹¹ Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. michael.scholl@neuro.gu.se.
• ¹² Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK. michael.scholl@neuro.gu.se.
• ¹³ Department of Clinical Physiology, Sahlgrenska University Hospital, Röda stråket 10B, 413 45, Gothenburg, Sweden. michael.scholl@neuro.gu.se.